Cognis expands production of active ingredients in France
This article was originally published in Scrip
Executive Summary
Cognis, a supplier of speciality chemicals and nutritional ingredients, has invested around €7 million into the extension of its R&D and production site for active ingredients in Pulnoy, France. The project, which was driven by increasing demand for active ingredients for cosmetics, should be completed in 2010. The site in Pulnoy belongs to Laboratories Serobiologiques (LS), Cognis's subsidiary since April 1999, which specialises in the development, manufacture and marketing of active ingredients (mostly for the cosmetic industry). Cognis is based in Monheim, Germany, and employs 7,600 people in 30 countries. It was part of Henkel, a German consumer products company, until 1999, when it became an independent business unit. Henkel sold the unit to private equity funds two years later.
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.